QR code

Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer

Summary: Therapy-induced molecular adaptation of triple-negative breast cancer is crucial for immunotherapy response and resistance. We analyze tumor biopsies from three different time points in the randomized neoadjuvant GeparNuevo trial (NCT02685059), evaluating the combination of durvalumab with...

Volledige beschrijving

Bewaard in:
Hoofdauteurs: Carsten Denkert, Andreas Schneeweiss, Julia Rey, Thomas Karn, Akira Hattesohl, Karsten E. Weber, Sivaramakrishna Rachakonda, Michael Braun, Jens Huober, Paul Jank, Hans-Peter Sinn, Dirk-Michael Zahm, Bärbel Felder, Claus Hanusch, Julia Teply-Szymanski, Frederik Marmé, Tanja Fehm, Jörg Thomalla, Bruno V. Sinn, Thorsten Stiewe, Michal Marczyk, Jens-Uwe Blohmer, Marion van Mackelenbergh, Christian Schem, Peter Staib, Theresa Link, Volkmar Müller, Elmar Stickeler, Daniel G. Stover, Christine Solbach, Otto Metzger-Filho, Christian Jackisch, Charles E. Geyer, Jr., Peter A. Fasching, Lajos Pusztai, Valentina Nekljudova, Michael Untch, Sibylle Loibl
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Elsevier 2024-11-01
Reeks:Cell Reports Medicine
Onderwerpen:
triple-negative breast cancer
immunotherapy
gene expression
PD-L1
neoadjuvant
pathway analysis
Online toegang:http://www.sciencedirect.com/science/article/pii/S2666379124005962
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items